DOCSLIB.ORG

Pre Triple Therapy . Multiple Fistulae Patent Application Publication Sep

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pre Triple Therapy . Multiple Fistulae Patent Application Publication Sep US 20170274071A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017/ 0274071 A1 AGRAWAL ( 43 ) Pub . Date : Sep . 28 , 2017 ( 54 ) COMPOSITIONS AND METHODS FOR (52 ) U .S . CI. TREATING CROHN ' S DISEASE AND CPC . .. A61K 39 / 39533 ( 2013 .01 ) ; A23C 9 / 123 RELATED CONDITIONS AND INFECTIONS (2013 .01 ) ; AIK 2039 /505 (2013 .01 ) ( 57 ) ABSTRACT ( 71 ) Applicant: CENTRE FOR DIGESTIVE In alternative embodiments , the invention provides a “ triple DISEASES , New South Wales (NSW ) combination ” therapy for treating , ameliorating and prevent (AU ) ing Crohn ' s Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis ) or related disorders and condi (72 ) Inventor : Gaurav AGRAWAL , Manly ( AU ) tions in mammals , such as paratuberculosis in mammals , or Johne ' s disease , including genetically - predisposed and (21 ) Appl. No. : 15 /483 , 702 chronic disorders , where the microbial or bacterial flora of the bowel is at least one causative or symptom -producing ( 22 ) Filed : Apr . 10 , 2017 factor ; and compositions for practicing same. In alternative embodiments , methods and compositions of the invention comprise or comprise use of therapies , medications , formu Related U . S . Application Data lations and pharmaceuticals comprising active agents that (63 ) Continuation of application No . 14 / 405 , 384 , filed on can suppress or eradicate the microbiota super- infection that Dec . 3 , 2014 , now Pat. No . 9 ,616 , 121 , filed as appli causes Crohn ' s Disease or paratuberculosis infection in cation No. PCT/ AU2013 /000587 on Jun . 4 , 2013 . mammals . In alternative embodiments , the methods and uses of the invention for treating , ameliorating and preventing ( 30 ) Foreign Application Priority Data Crohn ' s Disease and complications of Crohn ' s Disease , or related disorders and conditions in mammals , such as para Jun. 4 , 2012 (AU ) .. 2012902307 tuberculosis in mammals , or Johne ' s disease , comprises administration to an individual (human or mammal ) in need thereof : ( 1 ) an anti - TNFa composition , or a composition Publication Classification capable of down -modulating TNFa activity ; ( 2 ) a Hyper (51 ) Int. Cl. baric Oxygen Treatment, or HBOT; and ( 3 ) an anti- Myco A61K 39 /395 ( 2006 .01 ) bacterium avium sub species paratuberculosis MAP( ) ( an A23C 9 / 123 ( 2006 . 01 ) anti -MAP ) agent, composition or therapy. Pre triple therapy . Multiple fistulae Patent Application Publication Sep . 28 , 2017 US 2017 / 0274071 A1 FIG . 1 FIG . 2 Pre triple therapy. Multiple fistulae Completely healed mucosa Post tx FIG . 3 FIG . 4 Pre tx , Recto vaginal fistula Completely healed mucosa Post tx US 2017 /0274071 A1 Sep . 28 , 2017 COMPOSITIONS AND METHODS FOR heal Crohn ' s disease successfully , however healing time can TREATING CROHN ' S DISEASE AND be delayed and may take quite a few weeks or months even RELATED CONDITIONS AND INFECTIONS to induce remission . Anti -MAP Therapy can be slower in acting . When combined with immunosuppressants , such as CROSS -REFERENCE TO RELATED azathioprine or 6 -mercapto -purine , antibiotics do not work APPLICATIONS as they could in Crohn ' s disease possibly due to the [0001 ] This United States Utility patent application is a inhibition of the endogenous immunity . continuation of U . S . Utility patent application Ser . No . 14 / 405, 384 , filed Dec . 3 , 2014 (now pending) , which claims SUMMARY benefit of priority to and is a $ 371 national phase of Patent [0005 ] In alternative embodiments , the invention provides Cooperation Treaty Application Number PCT /AU2013 / methods , treatments or " triple combination " therapies , for 000587 , having an international filing date of Jun . 4 , 2013 , treating , ameliorating and /or preventing a Crohn ' s Disease , which claims benefit of priority to Australian Patent Appli or a complication of a Crohn ' s Disease , or a Crohn ' s cation Serial Number 2012902307, filed Jun . 4 , 2012 . The Disease -related fistulae , or related disorders and conditions aforementioned applications are expressly incorporated by in mammals , such as paratuberculosis in mammals , or reference in their entirety and for all purposes . Johne ' s disease , comprising administration to an individual, a mammal, or a patient in need thereof: TECHNICAL FIELD [0006 ] ( 1 ) an anti - TNFa composition or drug , or a [ 0002 ] This invention generally relates to medicine and composition or a drug capable of down -modulating or gastroenterology, pharmacology and microbiology . In alter down- regulating a TNFa activity ; native embodiments , the invention provides a “ triple com [0007 ] ( 2 ) a Hyperbaric Oxygen Treatment, or HBOT, bination ” therapy for treating , ameliorating and preventing or the medical use of oxygen at a level higher than Crohn ' s Disease ( or Crohn syndrome, terminal or distal atmospheric pressure ; and ileitis or regional enteritis ) or related disorders and condi [ 0008 ] ( 3 ) an anti -Mycobacterium avium sub species tions in mammals , such as paratuberculosis in mammals , or paratuberculosis (MAP ) ( also called M . paratubercu Johne ' s disease , including genetically -predisposed and losis or M . avium ssp .) ( an anti- MAP ) agent, compo chronic disorders , where the microbial or bacterial flora of sition , drug or therapy. the bowel is at least one causative or symptom -producing [0009 ] In alternative embodiments of the methods , treat factor; and compositions for practicing same. In alternative ments or “ triple combination ” therapies of the invention : embodiments , methods and compositions of the invention [0010 ] ( a ) the TNFa activity comprises causing an comprise or comprise use of therapies, medications, formu autophagy or an apoptosis in a cell; lations and pharmaceuticals comprising active agents that [ 0011 ] ( b ) the anti- TNFa composition or drug , or the can suppress or eradicate the microbiota super - infection that composition or drug capable of down -modulating or down causes Crohn ' s Disease or paratuberculosis infection in regulating a TNFa activity, comprises a protein , a peptide or mammals . In alternative embodiments , the methods and uses an antibody capable of specifically binding to a TNFa or a of the invention for treating, ameliorating and preventing TNFa - receptor or TNFa downstream effector; Crohn ' s Disease and complications of Crohn ' s Disease, or [ 0012 ] ( c ) the method , treatment or “ triple combination ” related disorders and conditions in mammals, such as para therapy of ( b ) , wherein antibody is or comprises : an inflix tuberculosis in mammals , or Johne ' s disease , comprises imab or a REMICADETM ( Janssen Biotech , Inc . ) ; an adali administration to an individual (human or mammal) in need mumab or a HUMIRATM ( Abbvie , North Chicago , Ill . ) ; a thereof: ( 1 ) an anti - TNFa composition , or a composition certolizumab , certolizumab pegol or a CIMZIATM , a goli capable of down -modulating TNFa activity ; ( 2 ) a Hyper mumab or a SIMPONITM ; a basiliximab or a SIMULECTTM ; baric Oxygen Treatment, or HBOT; and ( 3 ) an anti -Myco a daclizumab or a ZENAPAXTM ; an omalizumab or a bacterium avium sub species paratuberculosis (MAP ) (an XOLAIRTM ; or, any combination thereof; anti -MAP ) agent , composition or therapy . [0013 ] ( d ) the Hyperbaric Oxygen Treatment or the medi cal use of oxygen at a level higher than atmospheric pres BACKGROUND sure , comprises use or administration of: [0003 ] Crohn ' s disease is a chronic inflammatory condi [ 0014 ] a pressure of about 100 % oxygen , tion most likely caused by some form of infection . The most [0015 ] between about 90 % and 100 % oxygen , likely infective agent is Mycobacterium avium sub species [0016 ] oxygen at about 2 . 5 atm absolute, or between about paratuberculosis (MAP ) . Other infective agents that may 2 and 3 atm absolute , or cause Crohn ' s disease are Mycobacterium tuberculosis [0017 ] oxygen for about 90 minutes or for between about indistinguishable from Crohn ' s disease ; Entamoeba his 1 hour and 2 hours per session or treatment, or tolytica , Escherichia coli, Yersinia enterocolitica & atypical [0018 ] any combination thereof; Campylobacter species . Current therapies aim at reduction [00191 ( e ) the anti -Mycobacterium avium sub species of inflammation but there is an emerging trend to treat the paratuberculosis (MAP ) agent, composition , drug or underlying infection . therapy, comprises administration of : [ 0004 ) Infliximab can suppress a particular segment of the 10020 ] ( 1 ) a macrolide antibiotic ; immune system and exert similar effects in suppressing [0021 ] ( 2 ) a rifabutin and a macrolide antibiotic ; inflammation as azathioprine , 6 -mercapto -purine , Metho [ 0022 ] ( 3 ) a rifabutin or a MYCOBUTINTM , a trexate and Prednisone . Infliximab can have antimicrobial macrolide antibiotic , and a clofazimine ; activity against MAP and MAP containing bacteria . Anti [0023 ] ( 4 ) a combination of a rifabutin , a clarithromycin mycobacterium paratuberculosis ( Anti- MAP ) therapy can and a clofazimine or a LAMPRENETM ; US 2017 /0274071 A1 Sep . 28 , 2017 [ 0024 ] (5 ) any of ( 1 ) to ( 4 ) , wherein the macrolide [ 0043 ] (h ) the anti -MAP agent, composition , drug or antibiotic is or comprises: therapy of ( 3 ) is administered before, during, or after , or in [0025 ] a clarithromycin , or a TRUCLARTM , between sessions of, the Hyperbaric Oxygen Treatment, or CRIXANTM CLARITTTM CLARACTM , HBOT, or the medical use of oxygen at a level higher than
Load more

Recommended publications
  • W O 2015/175939 A1 19 November 2015 (19.11.2015) W I PO I P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2015/175939 A1 19 November 2015 (19.11.2015) W I PO I P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated,for every A61K 9/127 (2006.01) A01N 43/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2015/03 1079 DO, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 15 May 2015 (15.05.2015) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/993,439 15 May 2014 (15.05.2014) US (84) Designated States (unless otherwise indicated,for every 62/042,126 26 August 2014 (26.08.2014) US kind of regional protection available): ARIPO (BW, GH, 62/048,068 9 September 2014 (09.09.2014) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/056,296 26 September 2014 (26.09.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: INSMED INCORPORATED [US/US]; 10 DK, EE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Finderne Avenue, Building N'10, Bridgewater, NJ 08807- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 3365 (US).
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • In Vivo Antibacterial Activity of Vertilmicin, a New Aminoglycoside
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2009, p. 4525–4528 Vol. 53, No. 10 0066-4804/09/$08.00ϩ0 doi:10.1128/AAC.00223-09 Copyright © 2009, American Society for Microbiology. All Rights Reserved. In Vivo Antibacterial Activity of Vertilmicin, a New Aminoglycoside Antibioticᰔ Xue-Fu You,†* Cong-Ran Li,† Xin-Yi Yang, Min Yuan, Wei-Xin Zhang, Ren-Hui Lou, Yue-Ming Wang, Guo-Qing Li, Hui-Zhen Chen, Dan-Qing Song, Cheng-Hang Sun, Shan Cen, Li-Yan Yu, Li-Xun Zhao, and Jian-Dong Jiang* Laboratory of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China Received 18 February 2009/Returned for modification 4 May 2009/Accepted 15 July 2009 Vertilmicin is a novel aminoglycoside antibiotic with potent activity against gram-negative and -positive bacteria in vitro. In this study, we further evaluated the efficacy of vertilmicin in vivo in systemic and local infection animal models. We demonstrated that vertilmicin had relatively high and broad-spectrum activities against mouse systemic infections caused by Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Enterococcus faecalis. The 50% effective doses of subcutaneously administered vertilmicin were 0.63 to 0.82 mg/kg, 0.18 to 0.29 mg/kg, 0.25 to 0.99 mg/kg, and 4.35 to 7.11 mg/kg against E. coli, K. pneumoniae, S. aureus, and E. faecalis infections, respectively. The therapeutic efficacy of vertilmicin was generally similar to that of Downloaded from netimicin, better than that of gentamicin in all the isolates tested, and better than that of verdamicin against E.
    [Show full text]
  • Virtual Screen for Repurposing Approved and Experimental Drugs for Candidate Inhibitors of EBOLA Virus Infection [Version 2; Peer Review: 2 Approved]
    F1000Research 2015, 4:34 Last updated: 28 SEP 2021 RESEARCH ARTICLE Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [version 2; peer review: 2 approved] Veljko Veljkovic1, Philippe M. Loiseau 2, Bruno Figadere 2, Sanja Glisic1, Nevena Veljkovic1, Vladimir R. Perovic1, David P. Cavanaugh 3, Donald R. Branch4 1Center for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, Serbia 2Antiparasitic Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy Université Paris-Sud, Rue Jean-Baptiste Clément, F 92290- Chatenay-Malabry, France 3Bench Electronics, Bradford Dr., Huntsville, AL, 35801, USA 4Canadian Blood Services, Center for Innovation, 67 College Street, Toronto, Ontario, M5G 2M1, Canada v2 First published: 02 Feb 2015, 4:34 Open Peer Review https://doi.org/10.12688/f1000research.6110.1 Latest published: 16 Feb 2015, 4:34 https://doi.org/10.12688/f1000research.6110.2 Reviewer Status Invited Reviewers Abstract The ongoing Ebola virus epidemic has presented numerous 1 2 challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is version 2 proposed simple theoretical criterion for fast virtual screening of (revision) report molecular libraries for candidate inhibitors of Ebola virus infection. We 16 Feb 2015 performed a repurposing screen of 6438 drugs from DrugBank using this criterion and selected 267 approved and 382 experimental drugs version 1 as candidates for treatment of EVD including 15 anti-malarial drugs 02 Feb 2015 report report and 32 antibiotics. An open source Web server allowing screening of molecular libraries for candidate drugs for treatment of EVD was also established.
    [Show full text]
  • For the Heptoses of Septacidin and Hygromycin B
    D-Sedoheptulose-7-phosphate is a common precursor for the heptoses of septacidin and hygromycin B Wei Tanga,b,1, Zhengyan Guoa,1, Zhenju Caoa,b, Min Wanga, Pengwei Lia, Xiangxi Menga,b, Xuejin Zhaoa, Zhoujie Xiea, Wenzhao Wangc, Aihua Zhoud, Chunbo Loua, and Yihua Chena,b,2 aState Key Laboratory of Microbial Resources, and CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, 100101 Beijing, China; bCollege of Life Sciences, University of Chinese Academy of Sciences, 100049 Beijing, China; cState Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, 100101 Beijing, China; and dPharmacy School, Jiangsu University, 212013 Jiangsu, China Edited by Jerrold Meinwald, Cornell University, Ithaca, NY, and approved February 8, 2018 (received for review June 29, 2017) Seven-carbon-chain–containing sugars exist in several groups of im- β-substitution reaction (6). Not surprisingly, a LipK homolog protein- portant bacterial natural products. Septacidin represents a group of encoding gene, abmH, is present in the albomycin biosynthetic gene L-heptopyranoses containing nucleoside antibiotics with antitumor, an- cluster, indicating that the heptothiofuranose is formed through a tifungal, and pain-relief activities. Hygromycin B, an aminoglycoside similar carbon-chain extension process (5). anthelmintic agent used in swine and poultry farming, represents a Group II contains four highly reduced heptopyranoses from group of D-heptopyranoses–containing antibiotics. To date, very little several clinically important aminoglycoside antibiotics, including is known about the biosynthesis of these compounds. Here we se- gentamicin, verdamicin, and fortimicin (Fig. 1B) (7). Both in vivo quenced the genome of the septacidin producer and identified the and in vitro data support that a cobalamin-dependent radical septacidin gene cluster by heterologous expression.
    [Show full text]
  • What Does the Community Care About?
    720 BRITISH MEDICAL JOURNAL 25 SEPTEMBER 1976 study was that their susceptibility to all antibiotics (with the can suggest which only the ways in they will develop-CHCs Br Med J: first published as 10.1136/bmj.2.6038.720 on 25 September 1976. Downloaded from important exception of tetracyclines) has remained constant. have been working for no more than two years. Naturally There are 12 cephalosporins (including cefoxitin, strictly a enough the hundreds of councils have interpreted their cephamycin), of which only five are yet on the British market; functions and responsibilities in different ways, but already among these, much the most active were cephaloridine and there are pointers to the future. cephapirin. Only seven tetracyclines were tested, omitting Who are the members of the CHCs ? Half come from local rolitetracycline (German) and lymecycline and clomocycline authorities; one-third from voluntary organisations with (both Italian). It is interesting that chlortetracycline, the concerns such as child health, mental illness, and the elderly; original Aureomycin of 1948 and ancestor of the others, had and the rest are chosen by regional health authorities. Perhaps the highest activity of all against the species. The aminoglyco- we should not be surprised that they are predominantly sides, of which 11 were tested (not including framycetin or middle class, middle-aged men-teachers, managers, school paromomycin), are of less interest because they have little governors, and magistrates. Those with political ties are mostly place in treating streptococcal infections except in combination members of the Labour Party. Relatively few are retired, but with penicillin for endocarditis due to Streptococcus faecalis.
    [Show full text]
  • 6-Veterinary-Medicinal-Products-Criteria-Designation-Antimicrobials-Be-Reserved-Treatment
    31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0328244 A1 Eagle Et Al
    US 2015 0328244A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0328244 A1 Eagle et al. (43) Pub. Date: Nov. 19, 2015 (54) METHODS FOR TREATING PULMONARY A6II 45/06 (2006.01) NON-TUBERCULOUS MYCOBACTERIAL A 6LX 9/27 (2006.01) INFECTIONS (52) U.S. Cl. CPC ............. A6 IK3I/7036 (2013.01); A61K 9/127 (71) Applicant: Insmed Incorporated, Bridgewater, NJ (2013.01); A61 K9/0078 (2013.01); A61 K (US) 45/06 (2013.01) (72) Inventors: Gina Eagle, Morristown, NJ (US); Renu (57) ABSTRACT Gupta, Moorestown, NJ (US) Provided herein are methods for treating a pulmonary infec (21) Appl. No.: 14/713,926 tion in a patient in need thereof, for example, a nontubercu lous mycobacterial pulmonary infection for at least one treat (22) Filed: May 15, 2015 ment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a Related U.S. Application Data liposomal complexed aminoglycoside comprising a lipid (60) Provisional application No. 61/993,439, filed on May component comprising electrically neutral lipids and an ami 15, 2014, provisional application No. 62/042,126, noglycoside. Administration comprises aerosolizing the filed on Aug. 26, 2014, provisional application No. pharmaceutical composition to provide an aerosolized phar 62/048,068, filed on Sep. 9, 2014, provisional applica maceutical composition comprising a mixture of free ami tion No. 62/056.296, filed on Sep. 26, 2014. noglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition Publication Classification via a nebulizer to the lungs of the patient. The methods pro vided herein result in a change from baseline on the semi (51) Int.
    [Show full text]
  • Antibiotic Resistance Gene Resource and Assay List
    TechnicalInformation Antibiotic Resistance Gene Resource and Assay List Understanding the relationships between drugs and the genes that pathogens use to evade or neutralize them is imperative for successfully treating a range of infectious diseases. This resource provides an overview of these relationships and information about Microbial DNA qPCR Assays and Assay Kits, which specifically detect microbial antibiotic resistance genes. Overview Resistance to drugs that target pathogens is a serious public health concern. Resistance is the result of specific genes harbored by microorganisms that reduce the impact of drug molecules. Mechanisms employed by these gene products include covalent modification of the drug or target, removal of the drug from the cells, or activation of an alternative pathway. To understand an organism’s reaction to a drug or family of drugs, researchers must know which genes act on which set of drug compounds. Scientists can detect the presence of a specific antibiotic resistance gene in a sample by using QIAGEN’s Microbial DNA qPCR Assays and Assay Kits. These assays are highly sensitive and specific molecular analysis research tools, designed by a proprietary algorithm to test for the presence of microbial genes. The Microbial DNA qPCR Assays are a mix of two PCR primers and one 5′-hydrolysis probe that enables quantitative real-time PCR. They can screen for extremely small amounts of a target DNA sequence within a metagenomic sample. Microbial DNA qPCR Assay Kits (BBXX#####A) are a complete solution for real-time PCR-based microbial detection. Microbial DNA qPCR Assay Kits contain a Microbial DNA qPCR Assay, Microbial DNA Positive Control, Positive PCR Control, Microbial DNA-Free Water, and Microbial qPCR Mastermix — everything required for a successful qPCR run.
    [Show full text]
  • OCCASION This Publication Has Been Made Available to the Public on The
    OCCASION This publication has been made available to the public on the occasion of the 50th anniversary of the United Nations Industrial Development Organisation. DISCLAIMER This document has been produced without formal United Nations editing. The designations employed and the presentation of the material in this document do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations Industrial Development Organization (UNIDO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries, or its economic system or degree of development. Designations such as “developed”, “industrialized” and “developing” are intended for statistical convenience and do not necessarily express a judgment about the stage reached by a particular country or area in the development process. Mention of firm names or commercial products does not constitute an endorsement by UNIDO. FAIR USE POLICY Any part of this publication may be quoted and referenced for educational and research purposes without additional permission from UNIDO. However, those who make use of quoting and referencing this publication are requested to follow the Fair Use Policy of giving due credit to UNIDO. CONTACT Please contact [email protected] for further information concerning UNIDO publications. For more information about UNIDO, please visit us at www.unido.org UNITED NATIONS INDUSTRIAL DEVELOPMENT ORGANIZATION Vienna International Centre, P.O. Box 300, 1400 Vienna, Austria Tel: (+43-1) 26026-0 · www.unido.org · [email protected] DOC Coll·" ,. ,., Dis tr •. VIC Lib rFJ '-"---.....! 1 0 SEP 1985 LIMITED _,..
    [Show full text]
  • United States Patent (19) (11) 4,029,882 Wright (45) June 14, 1977
    United States Patent (19) (11) 4,029,882 Wright (45) June 14, 1977 54 SELECTIVE ACYLATION OF THE C-1 3,780,018 12/1973 Konishi et al. .............. 260/210 AB AMNO GROUP OF AMNOGLYCOSDE 3,781,268 12/1973 Kawaguchi et al. ......... 260/210 AB ANTIBOTCS 3,792,037 2/1974 Kawaguchi et al. ......... 260/210 AB 3,796,698 3/1974 Naito et al. ................. 260/210 AB (75) Inventor: John J. Wright, Orange, N.J. 3,796,699 3/1974 Naito et al. ...... ... 260/210 AB O 3,828,021 8/1974 Beattie et al. .... ... 260/210 AB 73) Assignee: Shering Corporation, Kenilworth, 3,868,360 2/1975 Daniels et al. .............. 260/210 AB 22 Filed: Mar. 19, 1974 O R PUBLICATIONS (21) Appl. No.: 452,586 Julian et al., “Chem. Abst.' vol. 75, 1971, p. 316592. vVs. Yavary 52)52l U.S. Cl. ................................. s 36/17fis s: Attorney,Primary Examiner-Johnnie Agent, or Firm-Carver R. Brown Joyner; Stephen I51) Int. C.’........................................ cost Coan; Raymond McDonald 58) Fieldield of Search ................ 260/210 AB, 33; 57 ABSTRACT A novel process for preparing novel 1-N-acyl-4,6-di 56) References Cited (aminoglycosyl)aminocyclitols is disclosed. The com UNITED STATES PATENTS pounds are useful as antibacterial agents. 3,244,590 4/1966 Schaffner et al. ........... 260/210 AB 3,753,973 8/1973 Umezawa et al. ........... 260/210 AB 18 Claims, No Drawings 4,029,882 2 and/or an amino substituent and separating the acyl SELECTIVE ACYLATION OF THE C-1 AMNO ated antibiotic from the reaction medium.
    [Show full text]